Bristol’s R&D marches on
"I'm pleased to say, R&D marches on," Bristol-Myers Squibb Chief Scientific Officer Elliott Sigal says at a recent strategic alliances conference in New York. "I am glad to be here, actually I'm pleased to get out period," he adds. Bristol's robust pipeline is one reason the firm has been rumored to be an acquisition candidate following the termination of CEO Peter Dolan Sept. 12 on the heels of a failed settlement with Apotex over Plavix generics (1"The Pink Sheet" Sept. 18, 2006, p. 3)...
You may also be interested in...
Bristol-Myers Squibb's search for a new CEO may be complicated by the widespread belief that the company is an acquisition target
ABHI’s Phil Brown believes the future of UK device regulation will be innovation-friendly and patient-responsive system – but doesn’t expect easy alignment with the EU. See what he had to say.
Biologics license application is preferred route to market, but if emergency authorization is given it should happen with full transparency and be communicated in a clear manner to strengthen public confidence, National Vaccine Advisory Committee says.